Compounders Research Compare

Estrella Immunopharma, Inc.(ESLA)

Biotechnology · EmeryVille, CA

$0.45+0.01 (+2.25%)

Delayed quote: Oct 6, 2026, 11:20 AM EDT

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

EmeryVille, CA

3 employees

www.estrellabio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Cheng Liu

View full financials

Estrella Immunopharma (ESLA) Price/FCF Ratio: History & Chart | TGMCharts

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T15:41:46.298Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:41:46.298Z.

Quote observation: 2026-10-06T15:38:24.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 18,401,513
TTM free cash flow · period ending 2026-06-30: -9,383,567

FMP input reference: 2d15fccd73dd71321fa30efb235d10704747171fee005d1a5dd6499fafc6c703

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ESLA Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

ESLA Competitors' Price/FCF Ratio

Estrella Immunopharma, Inc.

Current

Market Cap

$18.40M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NextCure, Inc.

Market Cap

$19.14M

Price/FCF Ratio

N/A

TTM Avg

278.20

3Y Avg

278.20

5Y Avg

278.20

Actuate Therapeutics Inc

Market Cap

$19.64M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

P3 Health Partners Inc.

Market Cap

$19.72M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Neuphoria Therapeutics Inc.

Market Cap

$18.59M

Price/FCF Ratio

N/A

TTM Avg

126.35

3Y Avg

822.33

5Y Avg

822.33

Cosmos Health Inc.

Market Cap

$17.75M

Price/FCF Ratio

N/A

TTM Avg

14.41

3Y Avg

40.25

5Y Avg

40.25

Marker Therapeutics, Inc.

Market Cap

$17.34M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Quantum BioPharma Ltd.

Market Cap

$21.12M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lipocine Inc.

Market Cap

$17.19M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Palatin Technologies, Inc.

Market Cap

$17.14M

Price/FCF Ratio

N/A

TTM Avg

2103.03

3Y Avg

2594.52

5Y Avg

2594.52

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Estrella Immunopharma, Inc. (ESLA)	$18.40M	N/A	N/A	N/A	N/A
NextCure, Inc. (NXTC)vs ›	$19.14M	N/A	278.20	278.20	278.20
Actuate Therapeutics Inc (ACTU)vs ›	$19.64M	N/A	N/A	N/A	N/A
P3 Health Partners Inc. (PIII)vs ›	$19.72M	N/A	N/A	N/A	N/A
Neuphoria Therapeutics Inc. (NEUP)vs ›	$18.59M	N/A	126.35	822.33	822.33
Cosmos Health Inc. (COSM)vs ›	$17.75M	N/A	14.41	40.25	40.25
Marker Therapeutics, Inc. (MRKR)vs ›	$17.34M	N/A	N/A	N/A	N/A
Quantum BioPharma Ltd. (QNTM)vs ›	$21.12M	N/A	N/A	N/A	N/A
Lipocine Inc. (LPCN)vs ›	$17.19M	N/A	N/A	N/A	N/A
Palatin Technologies, Inc. (PTN)vs ›	$17.14M	N/A	2103.03	2594.52	2594.52

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics